#China #Guangzhou #AI Healthcare #Chronic Disease #POMDOCTOR

POMDOCTOR LIMITED's Innovations in AI-Enabled Healthcare

In a groundbreaking update, POMDOCTOR LIMITED (NASDAQ: POM), a leader in digital healthcare, has announced advancements in its AI-enabled chronic disease management system. This development is set to enhance how chronic diseases are monitored and treated, making healthcare more personal and predictive than ever before.

The company has been focusing on optimizing its proprietary AI chronic disease management system, which draws on comprehensive real-world healthcare data, including medication histories, medical diagnoses, treatment records, patient behaviors, monitoring metrics, and healthcare payment data. By harnessing this multidimensional data, POMDOCTOR aims to refine key functionalities within its system.

One of the central goals of this initiative is to improve risk identification, provide personalized interventions for chronic diseases, and enhance the workflows between physicians and their patients. With continuous feedback from patient management data, the AI system is designed to learn and adapt, thus allowing healthcare providers to recognize trends and develop more tailored management strategies for patients. This cyclical learning approach marks a significant shift from episodic healthcare services to a more continuous, data-driven methodology for managing chronic conditions.

Expanding Real-World Data Applications

In addition to optimizing its management system, POMDOCTOR is broadening the commercial possibilities of its real-world data (RWD) applications. This includes conducting pharmaceutical real-world studies (RWS), engaging in evidence-based research collaborations, and providing B2B healthcare data services.

The RWD ecosystem composed by POMDOCTOR is rich and varied, integrating physiological, medication, behavioral, remote patient monitoring, and insurance data. This diverse foundation is not only instrumental for healthcare research but is also pivotal in providing viable management solutions and applications for ongoing patient care. These advancements are positioned as essential components within POMDOCTOR's diversified revenue structure, thereby adding substantial value to the company's operations.

Integrating In-Hospital and Out-of-Hospital Management

Furthermore, POMDOCTOR is pioneering integrated management pilots that operate both in hospital settings and in patients' homes. By establishing a robust physician service network and employing a comprehensive digital healthcare infrastructure, these pilots extend chronic disease management beyond single clinical encounters.

Patients can expect ongoing monitoring, consistent physician follow-ups, effective medication management, and personalized interventions as part of this initiative. Chairman and CEO of POMDOCTOR, Mr. Zhenyang Shi, stated that the company is dedicated to converting AI and healthcare data into actionable solutions applicable in real-world medical settings. He emphasized that by continually improving the chronic disease management system and advancing its RWD applications, POMDOCTOR is reinforcing the link between technological capabilities and commercial viability.

Conclusion

Looking ahead, POMDOCTOR LIMITED is poised to leverage the synergy of AI, real-world healthcare data, and physician-led interventions to innovate chronic disease management further. The company remains committed to developing advanced technology and commercializing its healthcare data and service infrastructures, ultimately aiming to improve patient outcomes and create long-term value for all stakeholders in the healthcare ecosystem. As these advancements unfold, it signals a promising evolution in the approach to chronic disease management, promising better patient care in an increasingly data-driven world.